Shipped and recorded revenue for initial order of conditioned media products to JENECELL equivalent to 144 million yen. Revenue will be recognized in Q4 of the fiscal year ending December 2026. Discussions continue with JENECELL for ongoing orders.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4593","jir_company_name":"Healios K.K.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4593-20261005-01.pdf","jir_short_summary":"Shipped and recorded revenue for initial order of conditioned media products to JENECELL equivalent to 144 million yen. Revenue will be recognized in Q4 of the fiscal year ending December 2026. Discussions continue with JENECELL for ongoing orders.","jir_summary":"### Transaction Overview\nHealios K.K. has shipped the initial order of conditioned media products to JENECELL and completed revenue recognition. This marks the first commercial shipment and represents a first step toward revenue opportunities beyond the regenerative medicine pipeline. We will continue discussions with JENECELL regarding shipment volumes and timing to secure ongoing orders. Conditioned media is expected to be used across multiple fields as a material for pharmaceuticals and cosmetics, and we plan to continue building relationships with other potential partners.\n\n### Outlook and Strategy\nWe will aim for continuous orders by continuing to discuss shipment volumes and timing with JENECELL. We will promote market expansion for product lines based on conditioned media and pursue relationships and negotiations with multiple partners to generate revenue opportunities beyond the regenerative medicine pipeline.","jir_financial_highlights":"Revenue Recognized: 144 million yen equivalent (Unknown)\nTiming of Revenue Recognition: Q4 of the fiscal year ending December 2026 (Unknown)","jir_category":"","jir_hashtags":"#NotAShareBuybackButSalesRelated, #ConditionedMedia, #RegenerativeMedicine","jir_key_figures":"Key Figure 1: 144 million yen equivalent (shipment and revenue recognized)\nKey Figure 2: Q4 of the fiscal year ending December 2026 (timing of revenue recognition)\nKey Figure 3: Unknown (shipment volumes and number of other partners are unknown)","jir_meta_title":"Shipment and Revenue Recognition of Conditioned Media Products to JENECELL \u2014 Initial Shipment Notice | October 2026","jir_meta_description":"Completed initial shipment of conditioned media products to JENECELL and recognized revenue. Revenue will be recognized in Q4 of the fiscal year ending December 2026. Discussions continue for ongoing orders.","jir_og_title":"Shipment to JENECELL of Conditioned Media \u2014 Initial Shipment and Revenue Recognition Notice","jir_og_description":"Completed initial shipment of conditioned media products and announced revenue recognition. Continuing discussions to expand future orders.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57247,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"sales_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-127450","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n